2023
Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial
Ghazi L, Yamamoto Y, Fuery M, O'Connor K, Sen S, Samsky M, Riello R, Dhar R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial. European Heart Journal 2023, 44: 4233-4242. PMID: 37650264, DOI: 10.1093/eurheartj/ehad512.Peer-Reviewed Original ResearchGuideline-directed medical therapyAcute heart failureMineralocorticoid receptor antagonistsHeart failureElectronic health recordsGDMT prescriptionPrimary outcomeEnzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitorsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorElectronic health record alertsEvidence-based regimenProviders of patientsReduced ejection fractionCotransporter 2 inhibitorsRelevant patient characteristicsTime of dischargePre-specified criteriaAHF hospitalizationEligible patientsInpatient initiationPatient characteristicsEjection fractionHospitalized patientsMedian ageEffect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure
Mentz R, Anstrom K, Eisenstein E, Sapp S, Greene S, Morgan S, Testani J, Harrington A, Sachdev V, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Velazquez E, Adams K, Bhatt K, DeWald T, Axsom K, Murthy S, Rich J, Testani J, Smith B, Vader J, McCulloch M, Skopicki H, Psotka M, Heroux A, Lala-Trindade A, Stevens G, Tang W, Lev Y, William P, Eberly A, Gottleib S, Haught W, Grafton G, Larned J, Tejwani L, Mody F, Krim S, Robinson M, Fang J, Adler A, Bell A, Banerjee D, Ruiz Duque E, Mizyed A, Rommel J, Arhinful J, Goyal P, Hall M, Hummel S, Shetty S, Haas D, Vilaro J, Alexy T, Herre J, Clark J, Ambrosy A, Gaglianello N, Ramasubbu K, Meadows J, Tabtabai S, Sherwood M, Hasni S, D'Urso M, Muneer B, Dunlap S, Davis W, Friedman D, Guglin M, Ferguson A, Abbate A, Smart F. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA 2023, 329: 214-223. PMID: 36648467, PMCID: PMC9857435, DOI: 10.1001/jama.2022.23924.Peer-Reviewed Original ResearchConceptsCause mortalityHeart failureTorsemide groupFurosemide groupTotal hospitalizationsCause hospitalizationEffects of torsemideDiuretic strategyPrespecified subgroupsSecondary outcomesEjection fractionMedian agePrimary outcomeHospitalizationMAIN OUTCOMEPatientsFurosemideMortalityMonthsTorsemidePrimary hypothesisSignificant differencesFinal dateOutcomesTrials
2022
Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial
Ghazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial. American Heart Journal 2022, 257: 111-119. PMID: 36493842, DOI: 10.1016/j.ahj.2022.12.002.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAcute heart failureHeart failurePragmatic trialElectronic health recordsSubstantial health care costsBest practice advisoryReduced ejection fractionUsual care armHealth recordsTime of dischargeEvidence-based careHealth care costsClinical decision support systemAHF patientsCare armEligible patientsHF hospitalizationInpatient initiationCardiovascular deathMedication classesEjection fractionMedical therapyPrimary outcomePractice advisory
2018
Clinical Utility and Prognostic Value of Right Atrial Function in Pulmonary Hypertension
Alenezi F, Mandawat A, Il'Giovine ZJ, Shaw LK, Siddiqui I, Tapson VF, Arges K, Rivera D, Romano MMD, Velazquez EJ, Douglas PS, Samad Z, Rajagopal S. Clinical Utility and Prognostic Value of Right Atrial Function in Pulmonary Hypertension. Circulation Cardiovascular Imaging 2018, 11: e006984. PMID: 30571314, PMCID: PMC6309911, DOI: 10.1161/circimaging.117.006984.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionArterial hypertensionRA dysfunctionLongitudinal strainComplete echocardiographic dataResults Study subjectsRight atrial functionRight atrial enlargementComposite of timeEarly diastolic SRPeak longitudinal strainRA conduitRA reservoirMultivariable adjustmentPulmonary hypertensionAtrial functionComposite outcomeDiastolic SRAtrial enlargementAtrial sizePrimary outcomePrognostic importancePrognostic valueAdverse outcomesMean ageLiraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial
Sharma A, Ambrosy AP, DeVore AD, Margulies KB, McNulty SE, Mentz RJ, Hernandez AF, Felker G, Cooper LB, Lala A, Vader J, Groake JD, Borlaug BA, Velazquez EJ. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Failure 2018, 5: 1035-1043. PMID: 30120812, PMCID: PMC6300815, DOI: 10.1002/ehf2.12334.Peer-Reviewed Original ResearchConceptsWeight loss agentsHeart failureEjection fractionHF hospitalizationNew York Heart Association functional class IIIGlucagon-like peptide-1 (GLP-1) receptor antagonistHeart Failure Treatment studyWeight lossAcute HF hospitalizationEfficacy of liraglutideRecent HF hospitalizationFunctional class IIILast study visitReduced ejection fractionAdvanced heart failureCardiovascular outcome trialsMedian ejection fractionAnalysis of patientsLiraglutide useMultivariable adjustmentStudy drugObese patientsOutcome trialsMedian agePrimary outcomeDeterminants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort
Okeke NL, Alenezi F, Bloomfield GS, Dunning A, Clement ME, Shah SH, Naggie S, Velazquez EJ. Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort. Journal Of Cardiac Failure 2018, 24: 496-503. PMID: 29964194, PMCID: PMC6231907, DOI: 10.1016/j.cardfail.2018.06.003.Peer-Reviewed Original ResearchConceptsLeft ventricular hypertrophyDiastolic dysfunctionTransthoracic echocardiogramVentricular hypertrophyHuman immunodeficiency virus-infected personsDuke University Medical CenterDefinite diastolic dysfunctionHIV Clinical CohortStructural myocardial abnormalitiesVirus-infected personsHuman immunodeficiency virusCells/University Medical CenterCD4 nadirsCD4 countViral suppressionPrimary outcomeImmune suppressionImmunodeficiency virusMyocardial abnormalitiesClinical cohortMedical CenterHigh riskImmune functionInfected persons
2016
Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy
Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, Desvigne-Nickens P, Sopko G, Rouleau JL. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. New England Journal Of Medicine 2016, 374: 1511-1520. PMID: 27040723, PMCID: PMC4938005, DOI: 10.1056/nejmoa1602001.Peer-Reviewed Original ResearchConceptsMedical therapy groupCardiovascular causesCoronary artery diseaseMedical therapyCABG groupArtery diseaseIschemic cardiomyopathySevere left ventricular systolic dysfunctionGuideline-directed medical therapyLeft ventricular systolic dysfunctionMajor secondary outcomesCoronary artery bypassPrimary outcome eventVentricular systolic dysfunctionArtery bypass surgeryCohort of patientsRate of deathSystolic dysfunctionBypass surgeryMedian durationSecondary outcomesSurvival benefitEjection fractionHeart failurePrimary outcome
2015
Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial
MacDonald MR, She L, Doenst T, Binkley PF, Rouleau JL, Tan R, Lee KL, Miller AB, Sopko G, Szalewska D, Waclawiw MA, Dabrowski R, Castelvecchio S, Adlbrecht C, Michler RE, Oh JK, Velazquez EJ, Petrie MC. Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. European Journal Of Heart Failure 2015, 17: 725-734. PMID: 26011509, PMCID: PMC4668269, DOI: 10.1002/ejhf.288.Peer-Reviewed Original ResearchConceptsIschemic Heart Failure (STICH) trialHeart Failure TrialDiabetes mellitusMedical therapyHigher LVEFSTICH trialCABG groupPrimary outcomeSurgical treatmentFailure TrialMED groupSmaller left ventricular volumesOptimal medical therapyTriple-vessel CADCoronary artery bypassOutcomes of patientsTriple vessel diseaseLeft ventricular volumeVessel CADArtery bypassCause mortalityClinical characteristicsClinical outcomesVessel diseaseCABG
2011
Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. New England Journal Of Medicine 2011, 364: 1607-1616. PMID: 21463150, PMCID: PMC3415273, DOI: 10.1056/nejmoa1100356.Peer-Reviewed Original ResearchConceptsMedical therapy groupCardiovascular causesCoronary artery diseaseMedical therapyCABG groupRate of deathArtery diseasePrimary outcomeMajor secondary outcomesCoronary artery bypassPrimary end pointArtery bypass surgeryLeft ventricular dysfunctionTreatment of patientsVentricular dysfunctionBypass surgerySecondary outcomesEjection fractionHeart failureCABGPatientsTherapyEnd pointHospitalizationDeath
2009
Coronary Bypass Surgery with or without Surgical Ventricular Reconstruction
Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL. Coronary Bypass Surgery with or without Surgical Ventricular Reconstruction. New England Journal Of Medicine 2009, 360: 1705-1717. PMID: 19329820, PMCID: PMC3265934, DOI: 10.1056/nejmoa0900559.Peer-Reviewed Original ResearchConceptsSurgical ventricular reconstructionCoronary artery diseaseVentricular reconstructionRate of deathCardiac causesLeft ventricular volumeArtery diseasePrimary outcomeVentricular volumeEnd-systolic volume indexComposite of deathCoronary artery bypassCoronary bypass surgeryLeft ventricular dysfunctionVentricular dysfunctionBypass surgeryCardiac symptomsEjection fractionHeart failureCABGStudy groupPatientsVolume indexHospitalizationAnatomical changes
2007
The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial
Velazquez EJ, Lee KL, O’Connor C, Oh JK, Bonow RO, Pohost GM, Feldman AM, Mark DB, Panza JA, Sopko G, Rouleau JL, Jones RH, Investigators S. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. Journal Of Thoracic And Cardiovascular Surgery 2007, 134: 1540-1547.e4. PMID: 18023680, PMCID: PMC3638867, DOI: 10.1016/j.jtcvs.2007.05.069.Peer-Reviewed Original ResearchConceptsIschemic Heart Failure (STICH) trialCoronary artery bypassHeart Failure TrialSurgical ventricular reconstructionArtery bypassMedical therapySurgical treatmentFailure TrialVentricular reconstructionPrimary outcomeNormal left ventricular sizeIntensive medical therapyLeft ventricular dysfunctionVentricular ejection fractionCoronary artery diseaseLeft ventricular sizeLong-term survivalQuality of lifeLeft ventricular volumeCardiac causesSubsequent hospitalizationVentricular dysfunctionArtery diseaseEjection fractionHeart failure
2006
Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction☆
Køber L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz R, Maggioni AP, Mareev V, Opolski G, Van de Werf F, Zannad F, Ertl G, Solomon SD, Zelenkofske S, Rouleau J, Leimberger JD, Califf RM. Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction☆. European Journal Of Heart Failure 2006, 8: 591-598. PMID: 16507350, DOI: 10.1016/j.ejheart.2005.11.007.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAngiotensin II Type 1 Receptor BlockersAtrial FibrillationCaptoprilCardiac Output, LowFemaleHumansMaleMiddle AgedMyocardial InfarctionOutcome Assessment, Health CarePrognosisProportional Hazards ModelsRisk AssessmentRisk FactorsSurvival AnalysisTetrazolesTime FactorsValineValsartanVentricular Dysfunction, LeftConceptsAcute myocardial infarctionCurrent atrial fibrillationPrior atrial fibrillationHeart failureAtrial fibrillationRisk of deathMyocardial infarctionCV eventsGreater long-term mortalityMajor CV eventsPrior heart failureAdverse CV eventsMajor cardiovascular eventsVentricular systolic dysfunctionLong-term mortalityHR of deathMajor risk indicatorsCardiovascular eventsSystolic dysfunctionVentricular dysfunctionPrimary outcomeVALIANT trialPatientsLVSDInfarction